The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports and stock price the company's current Operating Margin is 6.31%. At the end of 2024 the company had an Operating Margin of 6.60%.
Year | Operating Margin | Change |
---|---|---|
2024 | 6.60% | -42.67% |
2023 | 11.51% | -50.43% |
2022 | 23.21% | 0.44% |
2021 | 23.11% | 211.56% |
2020 | 7.42% | -70.71% |
2019 | 25.33% | 59.63% |
2018 | 15.87% | -42.06% |
2017 | 27.39% | -10.95% |
2016 | 30.75% | 5.79% |
2015 | 29.07% | 144.93% |
2014 | 11.87% | -58.17% |
2013 | 28.38% | -8.9% |
2012 | 31.15% | 48.13% |
2011 | 21.03% | -32% |
2010 | 30.92% | -26.13% |
2009 | 41.86% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 12.60% | 99.68% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 12.82% | 103.17% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 27.75% | 339.78% | ๐บ๐ธ USA |
![]() Amgen AMGN | 19.48% | 208.72% | ๐บ๐ธ USA |
![]() Gilead Sciences GILD | 23.75% | 276.39% | ๐บ๐ธ USA |
![]() Biogen BIIB | 17.85% | 182.88% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 13.32% | 111.09% | ๐ฌ๐ง UK |
![]() AstraZeneca AZN | 16.07% | 154.68% | ๐ฌ๐ง UK |
![]() Neurocrine Biosciences
NBIX | 20.63% | 226.94% | ๐บ๐ธ USA |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.